Immunotherapy
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
Feature
CMS proposes coverage of CAR T-cell therapy in trials
A final decision on the proposal is expected by May 2019.
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
From the Journals
Age-related gene expression may affect responses to RCC therapy
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-...